-
Product Insights
Alopecia Areata – Drugs In Development, 2023
Global Markets Direct’s, ‘Alopecia Areata - Drugs In Development, 2023’, provides an overview of the Alopecia Areata pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alopecia Areata, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Alopecia – Drugs In Development, 2023
Global Markets Direct’s, ‘Alopecia - Drugs In Development, 2023’, provides an overview of the Alopecia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alopecia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Track & Monitor
Innovation in pharma: deuterated drug synthesis
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the pharma industry’s deuterated drug synthesis segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ozuriftamab Vedotin in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ozuriftamab Vedotin in Oropharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ozuriftamab Vedotin in Oropharyngeal Cancer Drug Details: BA-3021 is under...
-
Product Insights
NewNet Present Value Model: Concert Pharmaceuticals Inc’s Deuruxolitinib Phosphate
Empower your strategies with our Net Present Value Model: Concert Pharmaceuticals Inc's Deuruxolitinib Phosphate report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Deuruxolitinib Phosphate in Alopecia Areata
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Deuruxolitinib Phosphate in Alopecia Areata report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Deuruxolitinib Phosphate in Alopecia Areata Drug Details: Deuruxolitinib phosphate (CTP-543, Deuterated...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Farletuzumab Ecteribulin in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Farletuzumab Ecteribulin in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Farletuzumab Ecteribulin in Peritoneal Cancer Drug Details: Farletuzumab ecteribulin (MORAb-202)...
-
Company Profile
Concert Pharmaceuticals Inc – Company Profile
Concert Pharmaceuticals Inc (Concert Pharma) is a late-stage clinical biotechnology company. It discovers and develops drugs for impacted patient care and addresses medical needs. The company develops its products using its deuterated chemical entity (DCE) platform for the treatment of autoimmune dermatological conditions, which includes alopecia areata. The alopecia areata occurs when the immune system attacks the hair follicles and is characterized as non-scarring hair loss. It also develops CTP-543, which is an oral inhibitor of Janus kinases JAK1 and...
Add to Basket -
Product Insights
Net Present Value Model: PCS-499
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model PCS-499 Drug Details PCS-499 (deuterated S-lisofylline,...
-
Product Insights
Net Present Value Model: Deuruxolitinib Phosphate
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Deuruxolitinib Phosphate Drug Details Deuruxolitinib phosphate...